SAMe

RELAXATION | GOOD MOOD | MOTIVATION

SAMe

RELAXATION | GOOD MOOD | MOTIVATION

What is SAMe?
S-adenosylmethionine, or SAMe, is an essential molecule that is produced naturally in the body, mainly by the liver, and plays many critical roles, including the production of neurotransmitters (serotonin, dopamine, and norepinephrine) and other critical proteins and hormones.

Where is SAMe extracted from?
The substance is obtained by biotechnological processes through the fermentation of Saccharomyces Cerevisiae, a single-celled fungus found in yeast.

What are the main characteristics of SAMe?
Because SAMe concentrations in the body decrease over time, supplementation with SAMe can be particularly useful for people with certain health conditions or under intense stress because it can help bring neurotransmitter production back to normal by restoring serotonin, norepinephrine, and dopamine levels.


Study titleConclusionsAuthors
Preliminary results of a randomized controlled trial conducted with a fixed combination of S- adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression.Based on the results of our study, it can be considered that the administration of SAMe is a viable and safe option for the treatment of individuals newly diagnosed with mild depression.Di Pierro F., Settembre R.
Preliminary results of a randomized controlled trial carried out with | IJGM
S-adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review.Existing studies on SAMe, used as monotherapy or in addition to other antidepressants, have shown encouraging and generally positive results.2020 - Alessandro Cuomo, Bruno Beccarini Crescenzi
S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review - PubMed

Study title

Conclusions

Authors

Preliminary results of a randomized controlled trial conducted with a fixed combination of S- adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression.
Based on the results of our study, it can be considered that the administration of SAMe is a viable and safe option for the treatment of individuals newly diagnosed with mild depression.
S-adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review.
Existing studies on SAMe, used as monotherapy or in addition to other antidepressants, have shown encouraging and generally positive results.